Mytelase

Active Ingredient(s): Ambenonium Chloride
FDA Approved: * May 1, 1956
Pharm Company: * SANOFI AVENTIS US
Category: Myasthenic Syndrome

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Mytelase Overview

Ambenonium (as ambenonium dichloride, trade name Mytelase) is a cholinesterase inhibitor[1] used in the management of myasthenia gravis. It is classified as reversible.[2] Mechanism of action Ambenonium exerts its actions against myasthenia gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. Myasthenia gravis occurs when the body produces antibodies against acetylcholine receptors, ...

Read more Mytelase Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ambenonium_chloride

Recent Mytelase Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ambenonium Chloride
  • Tablet: 10mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Ambenonium Chloride or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 10 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA